RaymondsIndex

In baseball, a sacrifice bunt is a strategic play. The batter gives up an out — deliberately — so another runner can advance. The team scores. The batter's statistics suffer. It is not failure. It is design. In corporate finance, the same logic applies. Not every company in a multi-asset portfolio is meant to generate returns for all stakeholders. Some are positioned to absorb losses, serve as debt warehouses, or fund exits for the controlling investor — while minority shareholders and institutional creditors absorb the downside. This is the sacrifice play. And Korea's Homeplus case is one of the most instructive recent examples. The Homeplus Timeline In 2015, MBK Partners — Korea's largest private equity firm — acquired Homeplus for approximately 7.2 trillion won, the largest PE deal in Korean history. Over the following decade, store assets were sold off in a series of sale-and-leaseback transactions, reportedly generating around 4 trillion won in proceeds. By Mar...

On the morning of May 6, 2026, the U.S. Department of Justice and the Securities and Exchange Commission unveiled one of the most sweeping insider trading prosecutions in recent memory. Thirty individuals were criminally charged; 21 faced simultaneous civil enforcement by the SEC. At the center of the scheme: a Yale Law-trained mergers and acquisitions attorney who had worked at Sidley Austin, Latham & Watkins, and Goodwin Procter — three of the most prominent M&A practices in the world. From 2018 to 2024, he allegedly extracted material nonpublic information from nearly 30 pending corporate transactions. That information moved through a structured network — participants reportedly used code words like "Torahs" and "Mitzvahs" — whose members traded ahead of public announcements and split the profits. Individual investors, reading the same press releases hours or days later, absorbed the other side of those trades. The Architecture of Information Asymmetry ...

In December 2025, the Bank of Japan raised its policy rate from 0.50% to 0.75%. The number looks small. The implication is not. After three decades during which money cost nothing, an estimated 210,000 zombie companies in Japan are being repriced in real time. Corporate bankruptcies crossed 10,000 cases in 2025 , the highest in 12 years. A new law expected to take effect in 2026, the Early Business Revitalization Act, will allow majority-vote private restructuring — a deliberate signal that the state no longer wants every distressed firm kept alive. Korea is on the same curve, on a different timeline. The Korea Exchange has confirmed 42 KOSDAQ companies are at delisting risk this cycle , up 4 from a year ago. Eleven of them — including Samyoung E&C, Jeil M&S, COSNINE, TOBESOFT, EOFLOW and Korea United Pharm — have now received two consecutive years of auditor disclaimers. Eight more, after three years, are already past decision and in suspended liquidation. KRX has compress...

 In April and May 2026, Korean biotech companies collectively issued more than 1.1 trillion won — approximately $807 million — in zero-coupon convertible bonds. The structure is simple: no interest, no maturity coupon, just a bet on share-price upside embedded in the conversion option. D&D Pharmatec alone raised 226.5 billion won ($166 million) in a single deal, the largest CB transaction in the Korean biotech sector this year (Seoul Economic Daily, 2026.05.03). For issuing companies, the logic is compelling. Capital arrives with no cash-outflow burden. The balance sheet swells. Optically, the company looks well-funded. But the question that matters to individual investors is not how much was raised. It's where the money went. The CGI Signal RaymondsIndex tracks this question through the Cash Governance Index (CGI) — one of four leading indicators that measure the structural health of a company's relationship with its own capital. CGI specifically monitors three patterns: t...

Introduction: Fermi’s 48-Hour Double Exit On April 20, 2026, Fermi — the AI nuclear power infrastructure startup co-founded by former Texas Governor and former U.S. Secretary of Energy Rick Perry — announced that founding CEO Toby Neugebauer had stepped down. Forty-eight hours later, CFO Miles Everson filed an SEC disclosure noting his resignation without “good reason.” Shares fell 22% in a single session. Market capitalization collapsed from nearly $20 billion at its October 2025 peak to $3.4 billion. The financials hadn’t moved. The executive network had. The CEI Signal: What Leadership Changes Tell Us Before Earnings Do RaymondsIndex tracks corporate health through four leading indicators. CEI — the Corporate Executive Index — monitors who enters and exits a company’s decision-making circle, and crucially, in what sequence and under what circumstances. When a CEO departs, the event is visible. What is harder to see is whether that departure reflects a deliberate strategy by controll...

In the first week of May 2026, two stories landed on opposite sides of the Pacific — and they told the same story. In Seoul, The Korea Herald and The Investor reported that national security reviews are no longer a predictable procedural step in Korean cross-border M&A. They have become a strategic weapon. Lawmakers from both ruling and opposition parties are now pushing legislation that would extend security screening to minority stake acquisitions and indirect investments — not just controlling interests. The Korea Zinc vs. MBK battle in 2024 was the opening act: a domestic private equity firm with significant foreign investor exposure was subjected to national security arguments by the target company's management as a defense mechanism. In Boston, Roche announced on May 7 that it has entered into a definitive merger agreement to acquire PathAI — an AI-powered digital pathology company — for $750 million upfront, with milestone payments of up to $300 million additional, for a...